TVM Capital Life Science
Valentina Agostoni is a Senior Associate at TVM Capital Life Science. Prior to that, Valentina worked as a Preclinical Development Scientist at Mperia Therapeutics Inc and Versantis AG. Valentina has a background in Pharmaceutical Sciences and Biomedical Sciences, with a focus on nanoscale drug delivery systems and CAR T-cell therapy. Valentina holds a PhD from Université Paris-Saclay and has conducted research on identifying molecular markers for renal carcinoma.
This person is not in any offices
TVM Capital Life Science
TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.